Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

FibroBiologics, Inc. - Common Stock (NQ:FBLG)

0.4209 -0.0119 (-2.75%)
Streaming Delayed Price Updated: 4:00 PM EDT, Oct 28, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 791,989
Open 0.4300
Bid (Size) 0.4203 (2)
Ask (Size) 0.4212 (5)
Prev. Close 0.4328
Today's Range 0.4150 - 0.4300
52wk Range 0.3901 - 3.890
Shares Outstanding 38,262,586
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
FibroBiologics to Present at Bio-Europe 2025
From FibroBiologics, Inc.
Via GlobeNewswire
FibroBiologics to Present at the 2025 ThinkEquity Conference
From FibroBiologics, Inc.
Via GlobeNewswire

Performance

YTD
-78.8%
-78.8%
1 Month
-31.2%
-31.2%
3 Month
-30.6%
-30.6%
6 Month
-59.5%
-59.5%
1 Year
-85.1%
-85.1%

More News

Read More
BioVie and FibroBiologics Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
Via ACCESS Newswire
FibroBiologics to Present at 2025 Cell & Gene Meeting on the Mesa
From FibroBiologics, Inc.
Via GlobeNewswire
FibroBiologics Leadership Authors Opinion Editorial Highlighting Fibroblast Cells' Therapeutic Advantages Over Traditional Stem Cell Therapies
From FibroBiologics, Inc.
Via GlobeNewswire
FibroBiologics Announces Positive IND-Enabling Updates Demonstrating Potential of Fibroblast Spheroids in Chronic-Relapse Psoriasis Treatment
From FibroBiologics, Inc.
Via GlobeNewswire
FibroBiologics Announces Significant Advancements in Bone Marrow Organoid Platform Enabling Development for Cancer and Immune-Related Therapies
From FibroBiologics, Inc.
Via GlobeNewswire
FibroBiologics to Present at the H.C. Wainwright 27th Annual Global Investment Conference
From FibroBiologics, Inc.
Via GlobeNewswire
FibroBiologics Reports Second Quarter 2025 Financial Results and Provides Corporate Update
From FibroBiologics, Inc.
Via GlobeNewswire
FibroBiologics Files Patent for Methods of Generating Multipotent Cells from Donor Tissue for Clinical Applications
From FibroBiologics, Inc.
Via GlobeNewswire
Brag House and FibroBiologics Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
Via ACCESS Newswire
FibroBiologics to Present at the Advanced Wound Care Summit USA
From FibroBiologics, Inc.
Via GlobeNewswire
FibroBiologics Confirms Ability to Manufacture CybroCell™ for Degenerative Disc Disease and Cartilage Repair Programs from Existing CYWC628 Master Cell Bank
From FibroBiologics, Inc.
Via GlobeNewswire
FibroBiologics’ to Present at Exclusive Live Investor Webinar and Q&A Session on July 10
From FibroBiologics, Inc.
Via GlobeNewswire
Fathom Holdings and FibroBiologics Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
Via ACCESS Newswire
FibroBiologics Closes Third $5 Million Tranche of $25 Million Financing
From FibroBiologics, Inc.
Via GlobeNewswire
FibroBiologics to Present at the BIO International Convention 2025
From FibroBiologics, Inc.
Via GlobeNewswire
FibroBiologics Appoints Jason D. Davis, CPA, as Chief Financial Officer
From Fibrobiologics, Inc.
Via GlobeNewswire
FibroBiologics Presents at the Society for Investigative Dermatology Annual Meeting
From Fibrobiologics, Inc.
Via GlobeNewswire
FibroBiologics Reports First Quarter 2025 Financial Results and Provides Corporate Update
From Fibrobiologics, Inc.
Via GlobeNewswire
FibroBiologics Presenting at the ThymUS 2025 Meeting
From Fibrobiologics, Inc.
Via GlobeNewswire
FibroBiologics to Present at The Cell & Gene Meeting on the Mediterranean
From Fibrobiologics, Inc.
Via GlobeNewswire
FibroBiologics Unveils New and Expanded Houston Laboratory Space to Pursue Innovation and Breakthroughs in Fibroblast-Based Therapeutics
From Fibrobiologics, Inc.
Via GlobeNewswire
FibroBiologics Announces Scientific Advancement in Confirmation Results of Brain Tissue Repair
From Fibrobiologics, Inc.
Via GlobeNewswire
FibroBiologics Reports Full Year 2024 Financial Results and Provides Corporate Update
From Fibrobiologics, Inc.
Via GlobeNewswire

Frequently Asked Questions

Is FibroBiologics, Inc. - Common Stock publicly traded?
Yes, FibroBiologics, Inc. - Common Stock is publicly traded.
What exchange does FibroBiologics, Inc. - Common Stock trade on?
FibroBiologics, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for FibroBiologics, Inc. - Common Stock?
The ticker symbol for FibroBiologics, Inc. - Common Stock is FBLG on the Nasdaq Stock Market
What is the current price of FibroBiologics, Inc. - Common Stock?
The current price of FibroBiologics, Inc. - Common Stock is 0.4209
When was FibroBiologics, Inc. - Common Stock last traded?
The last trade of FibroBiologics, Inc. - Common Stock was at 10/28/25 04:00 PM ET
What is the market capitalization of FibroBiologics, Inc. - Common Stock?
The market capitalization of FibroBiologics, Inc. - Common Stock is 16.10M
How many shares of FibroBiologics, Inc. - Common Stock are outstanding?
FibroBiologics, Inc. - Common Stock has 16M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.